Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 3 6Phase 1/2 4Phase NA 3Phase 4 3Phase 2/3 3

Status

Unknown 6Not yet recruiting 3Recruiting 2Completed 1

Sponsor Class

UNKNOWN 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 5Oxaliplatin 5Cyclophosphamide 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3Azacitidine 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × sintilimab × Clear all
NCT06977061 2025-05-16

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Second Affiliated Hospital of Nanchang University

Phase 2/3 Not yet recruiting
30 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
668 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05484024 2022-08-02

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

ChineseAMS

Phase 2/3 Not yet recruiting
588 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡